

JUN 20 2005

5136261355

P.01/09


Procter & Gamble - I.P. Division**IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

**FACSIMILE TRANSMITTAL SHEET AND
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8****TO: - United States Patent and Trademark Office**

Fax No. 703-872-9306 Phone No.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on 6/20, 2005, to the above-identified facsimile number.

 (Signature)

FROM: Laura L. Frieke (Typed or printed name of person signing Certificate)

Fax No. 513-626-1355 Phone No. 513-626-2721

Listed below are the item(s) being submitted with this Certificate of Transmission:**

- 1) Supplemental IDS (Original + 1)
- 2) PTO SB08A
- 3)
- 4)
- 5)

Number of Pages including this Page: 9

Inventor(s): Donald Lynn Bissett et al.

S.N.: 10/814,759

Filed: March 31, 2004

Docket No.: 8482D

Comments:

**Note: Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper.

Certification of Mailing or Facsimile Transmittal I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being submitted as indicated below: <input checked="" type="checkbox"/> Facsimile transmittal to the U.S. Patent and Trademark Office via fax number (703) 872-9306	
Name	LAURA L. PRISTO
Registration No. (if applicable)	52,920
Signature	<i>Laura L. Pristo</i>
Date	6/20/05

JUN 20 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/814,759
 Applicant(s) : Donald Lynn Bissett et al.
 Filed : March 31, 2004
 Title : SKIN CARE COMPOSITIONS CONTAINING
 A SUGAR AMINE
 TC/A.U. : 7736
 Examiner :
 Conf. No. : 7736
 Docket No. : 8482D
 Customer No. : 27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or

within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☒ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.


5. ☐ Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[X] All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 8482, U.S. Patent Application Serial No. 10/097,716, filed March 13, 2002. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Laura L. Frieko

Typed or printed name

Registration No. 52,920

(513) 626-2721

Date: 6/20/05
Customer No. 27752
(IDS.doc) (Last Revised 4/11/2005)

Certification of Mailing or Facsimile Transmission I hereby certify that I have reasonable basis to expect that, on the date shown below, the correspondence is being submitted as indicated below: By (mailing transmitted to the U.S. Patent and Trademark Office via fax number (703) 872-4106)	
Laura L. Fricko Name	52,920 Registration No. (if applicable)
<i>Laura L. Fricko</i> Signature	
6/20/05 Date	

RECEIVED
CENTRAL FAX CENTER
JUN 20 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/814,759
 Applicant(s) : Donald Lynn Bissett et al.
 Filed : March 31, 2004
 Title : SKIN CARE COMPOSITIONS CONTAINING A SUGAR AMINE
 TC/A.U. : 7736
 Examiner :
 Conf. No. : 7736
 Docket No. : 8482D
 Customer No. : 27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or

within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☒ **37 C.F.R. §1.97(b)(3)** - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4)** - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment** - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.


5. ☐ Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[X] All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 8482, U.S. Patent Application Serial No. 10/097,716, filed March 13, 2002. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Laura L. Fricko

Typed or printed name

Registration No. 52,920

(513) 626-2721

Date: 6/20/05
Customer No. 27752
(IDS.doc) (Last Revised 4/11/2005)

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

SHEET 1 of 2

COMPLETE IF KNOWN

Application Number	10/814,759
Confirmation Number	7736
Filing Date	Marh 31, 2004
First Named Inventor	Donald Lynn Bissett
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	8482D

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-4,590,067	05-20-1986	Meisner	
	2	US-5,015,470	05-14-1991	Gibson	
	3	US-5,081,151	01-14-1992	Davis et al.	
	4	US-5,416,075	05-16-1995	Carson et al.	
	5	US-5,571,503	11-06-1996	Mausner	
	6	US-5,601,833	02-11-1997	Ribier et al.	
	7	US-5,650,166	07-22-1997	Ribier et al.	
	8	US-5,654,266	08-05-1997	Chen et al.	
	9	US-6,147,054	11-14-2000	De Paoli Ambrosi	
	10	US-6,217,888	04-17-2001	Oblong	
	11	US-6,413,525	07-02-2002	Mammone et al.	
	12	US-6,492,349 B1	12-10-2003	Henderson	
	13	US-6,495,531 B2	12-17-2002	Vanden Berghe	
	14	US-6,524,592	02-25-2003	Yu et al.	
	15	US-6,808,716 B2	10-26-2004	Yu et al.	
	16	US-2003/0072770 A1	04-17-2003	McAnalley et al.	
	17	US-2005/0048008 A1	03-03-2005	Gupta	
EXAMINER			DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 11/5/2004)

Please type a plus sign (+) inside this box → [+]

PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a currently valid control number.</p> <p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> <p>SHEET 2 of 2</p>	COMPLETE IF KNOWN	
	Application Number	10/814,739
	Confirmation Number	7736
	Filing Date	March 31, 2004
	First Named Inventor	Donald Lynn Bissett
	Group Art Unit	1614
	Examiner Name	
Attorney Docket Number	8482D	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ²	Number ³	Kind Code ⁴ (if known)				
	18	CN	1067246 C		06-20-2001	Xu		
	19	CN	1156028A		08-06-1997	Xu		
	20	EP	0561489		09-22-1993	Barr et al.		
	21	EP	0779097 B1		06-11-2003	Watanabe et al.		
	22	JP	02243611		09-27-1990	Shimizu et al..		
	23	JP	02-265,458		10-30-1990	Ochi et al.		
	24	JP	2578341 B2		02-05-1997	Katsuo et al.		
	25	JP	61-129,123 A		06-17-1986	Arimoto et al.		
	26	JP	62036306		02-17-1987	Mishima et al.		

NON PATENT LITERATURE DOCUMENTS

EXAMINEE R INITIALS*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	27	Hardman et al. "Goodman & Gilman's The Pharmacological Basis of Therapeutics" (9 th ed, 1996) pages 51 and 57-58.	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 11/4/2004)